Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Condition: Histiocytosis Intervention: Drug: Vemurafenib Sponsors: Anna Raciborska; Maria Sklodowska-Curie Institute - Oncology Center; Łukasiewicz Research Network; Wrocław University of Environmental and Life Sciences Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials